The concurrence of FLT3-ITD mutation is an adverse prognostic finding in CEBPA mutated-AML patients (23). RUNX1 encodes the DNA binding alpha subunit of the core binding factor (CBFalpha) that is involved in the normal differentiation of hematopoietic cells. This evidence concerns the gene FLT3 and acute myeloid leukemia.